Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708201 | 0.89 | GRIN2B (0.48) | ALDH1A1CYP2D6KDM4EHRH3 | |
| SCHEMBL6708041 | 0.83 | MCHR1 (0.50) | ALDH1A1CYP2D6CYP2C9HIF1AHRH3 | |
| SCHEMBL6708138 | 0.79 | L3MBTL1 (0.50) | ALDH1A1KDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL6704481 | 0.78 | MCHR1 (0.43) | ALDH1A1CYP2D6CYP2C9HIF1AKDM4E | |
| SCHEMBL6223200 | 0.78 | HRH3 (0.61) | ALDH1A1CYP2D6KDM4EHRH3HDAC1 | |
| SCHEMBL6706724 | 0.78 | ALDH1A1 (0.49) | ALDH1A1KDM4EHRH3PRMT6POLB | |
| SCHEMBL6708212 | 0.77 | L3MBTL1 (0.41) | ALDH1A1KDM4EHRH3HDAC1HDAC8 | |
| SCHEMBL28610633 | 0.76 | PRMT6 (0.63) | ALDH1A1CYP2D6CYP2C9HIF1AKDM4E | |
| SCHEMBL4840236 | 0.76 | CYP2D6 (0.46) | ALDH1A1CYP2D6CYP2C9HIF1APRMT6 | |
| SCHEMBL6708231 | 0.75 | ACHE (0.44) | ALDH1A1CYP2D6CYP2C9HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | ALDH1A1 3363/4885CYP2D6 1590/4885CYP2C9 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.